Triple Agonist
Also known as: Triple receptor agonist, GGG agonist, Triagonist
Triple Agonist refers to a peptide medication that activates three receptors simultaneously, typically GLP-1, GIP, and glucagon receptors. Retatrutide is the most advanced triple agonist in clinical development, showing unprecedented weight loss in trials but not yet FDA-approved.
Last updated: January 28, 2026
What is a Triple Agonist?
A triple agonist is a peptide designed to activate three receptor types simultaneously. In metabolic research, this typically refers to molecules targeting GLP-1, GIP, and glucagon receptors—the three key hormonal pathways involved in metabolism.
Evolution of incretin therapies:
- Single agonist: GLP-1 only (semaglutide, liraglutide)
- Dual agonist: GLP-1 + GIP (tirzepatide)
- Triple agonist: GLP-1 + GIP + Glucagon (retatrutide)
The Three Receptor Targets
| Receptor | Primary Effects | Contribution to Weight Loss |
|---|---|---|
| GLP-1R | Appetite ↓, insulin ↑, gastric emptying ↓ | ~60% of effect |
| GIPR | Insulin ↑, fat metabolism, synergy | ~15% of effect |
| GCGR | Energy expenditure ↑, glycogenolysis | ~25% of effect |
Why Add Glucagon Agonism?
Glucagon receptor activation adds unique metabolic effects:
- Increased energy expenditure — Stimulates thermogenesis
- Enhanced lipolysis — Promotes fat breakdown
- Hepatic effects — Increases metabolic rate
- Potential for greater weight loss — Complementary to GLP-1 effects
Challenge: Glucagon raises blood sugar, so must be balanced by GLP-1/GIP insulin effects.
Retatrutide: Lead Triple Agonist
Retatrutide (LY3437943) is Eli Lilly’s triple agonist in Phase 3 development:
Phase 2 Trial Results:
| Dose | Weight Loss (48 weeks) | Participants ≥25% Loss |
|---|---|---|
| 4 mg | -17.5% | 25% |
| 8 mg | -22.8% | 55% |
| 12 mg | -24.2% | 63% |
| Placebo | -2.1% | 0% |
These results exceed any previously reported in obesity medication trials.
Triple vs Dual vs Single Agonist
| Metric | Semaglutide 2.4mg | Tirzepatide 15mg | Retatrutide 12mg |
|---|---|---|---|
| Mechanism | GLP-1 | GLP-1+GIP | GLP-1+GIP+Glucagon |
| Weight loss | ~15% | ~21% | ~24% |
| ≥20% weight loss | ~32% | ~57% | ~71% |
| Status | Approved | Approved | Phase 3 |
Note: Cross-trial comparisons have limitations
Other Triple Agonists in Development
| Compound | Developer | Receptors | Status |
|---|---|---|---|
| Retatrutide | Eli Lilly | GLP-1/GIP/Glucagon | Phase 3 |
| VK2735 | Viking Therapeutics | GLP-1/GIP (Glucagon antagonist) | Phase 2 |
| HM15211 | Hanmi Pharmaceutical | GLP-1/GIP/Glucagon | Phase 2 |
Safety Considerations
Triple agonists have shown similar side effects to dual and single agonists:
Common:
- Nausea, vomiting, diarrhea
- Decreased appetite
- Injection site reactions
Specific concerns:
- Glucagon component may affect blood sugar in some patients
- Long-term effects of triple receptor activation unknown
- Liver enzyme elevations observed (under investigation)
Current Status
As of early 2026:
- Not FDA-approved — Phase 3 trials ongoing
- Estimated approval: Late 2026 or 2027 if trials successful
- Target indications: Obesity, type 2 diabetes, MASH (metabolic liver disease)
Research Implications
Triple agonism represents the frontier of incretin research:
- Demonstrates potential for 25%+ body weight reduction
- Raises questions about physiological limits of pharmacological weight loss
- May address metabolic liver disease (MASH) with glucagon effects
- Long-term data will determine place in therapy
This entry is for educational purposes only. Retatrutide is investigational and not approved for any use. Clinical trial participation is the only access route.
Related Peptides
Related Terms
Disclaimer: This glossary entry is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for medical questions.